Biomarker detection technologies and future directions

Nimse, Satish Balasaheb; Sonawane, Mukesh Digambar; Song, Ki-Bong; Kim, Taisun

doi:10.1039/c5an01790d

Cited by 217 publications

(148 citation statements)

References 155 publications

Supporting

Mentioning

148

Contrasting

Order By: Relevance

“…Most of these approaches still lack accuracy, sensitivity and specificity required for diagnostic application. Advantages and limitations of these methods have been compared for the prostate specific antigen (PSA) biomarker detection [159]. Different cancer biosensors and their characteristics were recently reported [160].…”

Section: Applications Of Aptamers In Oncologymentioning

confidence: 99%

Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers

Mercier

Dontenwill

Choulier

2017

Cancers

View full text Add to dashboard Cite

Aptamers are nucleic acids referred to as chemical antibodies as they bind to their specific targets with high affinity and selectivity. They are selected via an iterative process known as ‘selective evolution of ligands by exponential enrichment’ (SELEX). Aptamers have been developed against numerous cancer targets and among them, many tumor cell-membrane protein biomarkers. The identification of aptamers targeting cell-surface proteins has mainly been performed by two different strategies: protein- and cell-based SELEX, when the targets used for selection were proteins and cells, respectively. This review aims to update the literature on aptamers targeting tumor cell surface protein biomarkers, highlighting potentials, pitfalls of protein- and cell-based selection processes and applications of such selected molecules. Aptamers as promising agents for diagnosis and therapeutic approaches in oncology are documented, as well as aptamers in clinical development.

show abstract

Section: Applications Of Aptamers In Oncologymentioning

confidence: 99%

Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers

Mercier

Dontenwill

Choulier

2017

Cancers

View full text Add to dashboard Cite

show abstract

“…Progression of disease is very often associated with the expression of multiple biomarkers that make up a “biomarker panel”. For example, recent reports indicate that no individual biomarker is ideal for the diagnosis and prognosis of pancreatic cancer [109]. Another example is a pattern of miRNA molecules associated with a specific type of cancer [110,111].…”

Section: Multiplexing With Sers Immunoassaymentioning

confidence: 99%

Surface-Enhanced Raman Scattering-Based Immunoassay Technologies for Detection of Disease Biomarkers

et al. 2017

View full text Add to dashboard Cite

Detection of biomarkers is of vital importance in disease detection, management, and monitoring of therapeutic efficacy. Extensive efforts have been devoted to the development of novel diagnostic methods that detect and quantify biomarkers with higher sensitivity and reliability, contributing to better disease diagnosis and prognosis. When it comes to such devastating diseases as cancer, these novel powerful methods allow for disease staging as well as detection of cancer at very early stages. Over the past decade, there have been some advances in the development of platforms for biomarker detection of diseases. The main focus has recently shifted to the development of simple and reliable diagnostic tests that are inexpensive, accurate, and can follow a patient’s disease progression and therapy response. The individualized approach in biomarker detection has been also emphasized with detection of multiple biomarkers in body fluids such as blood and urine. This review article covers the developments in Surface-Enhanced Raman Scattering (SERS) and related technologies with the primary focus on immunoassays. Limitations and advantages of the SERS-based immunoassay platform are discussed. The article thoroughly describes all components of the SERS immunoassay and highlights the superior capabilities of SERS readout strategy such as high sensitivity and simultaneous detection of a multitude of biomarkers. Finally, it introduces recently developed strategies for in vivo biomarker detection using SERS.

show abstract

“…Monitoring of biomarkers from biological fluid samples and tissues is of great importance for detection of these illnesses. World Health Organization (WHO) defines that “A biomarker is any substance, structure, or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease.” . It can be genes, proteins, lipids, or metabolites, which are present in tumor tissues, serum, or body fluids (e.g.…”

Section: Introductionmentioning

confidence: 99%

Recent applications of paper‐based point‐of‐care devices for biomarker detection

Suntornsuk

2019

Electrophoresis

View full text Add to dashboard Cite

Detection of biomarkers is essential for diagnosis and prognosis of diseases for healthcare teams to provide timely appropriate treatments. Reliable, inexpensive, and sensitive devices are desirable to serve this purpose. Paper‐based analytical devices (PADs) have gained enormous attention during the past decade as point‐of‐care devices for biomarker detection due to their simplicity, portability, and biocompatibility. Importantly, the devices highly comply with the WHO “ASSURED” concept (i.e. Affordable, Sensitive, Specific, User‐friendly, Rapid and Robust, Equipment free, and Deliverable to end‐users). Thus, PADs could be sustainably alternative tools for biomarker detection, especially in resources‐constraint areas where budget, skillful operators, and health infrastructure are limited. First, this review introduces overviews of biomarkers, their detection and brief history of PADs. Second, description of common fabrication and detection techniques in PADs are provided. Then, it highlights recent state of the art technologies and applications of PADs for various biomarker detection published during 2018 to May 2019. Applications for tumor marker, cardiac and coronary heath disease, and metabolic disorder biomarker detection are tabulated and selected examples are described in details. Finally, it discusses the current challenges, advances, and novel applications of PADs. The review would be valuable for healthcare workers using PADs as cost‐effective point‐of‐care devices for biomarker detection and for researchers working on future developments of the devices.

show abstract

Biomarker detection technologies and future directions

Cited by 217 publications

References 155 publications

Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers

Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers

Surface-Enhanced Raman Scattering-Based Immunoassay Technologies for Detection of Disease Biomarkers

Recent applications of paper‐based point‐of‐care devices for biomarker detection

Contact Info

Product

Resources

About